Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma.
Asthma
Dupilumab
Eosinophil
Fractional exhaled nitric oxide
Sputum
Journal
Allergology international : official journal of the Japanese Society of Allergology
ISSN: 1440-1592
Titre abrégé: Allergol Int
Pays: England
ID NLM: 9616296
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
15
05
2024
revised:
29
07
2024
accepted:
11
08
2024
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
14
9
2024
Statut:
aheadofprint
Résumé
The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count. This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline. Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV Type-2 biomarkers may act as indicators of improvement in FEV
Sections du résumé
BACKGROUND
BACKGROUND
The therapeutic effectiveness of dupilumab for severe asthma in real-world settings is yet to be prospectively investigated across multiple institutions, and uncertainties persist regarding predictive factors for its effectiveness. We aimed to assess the effectiveness of dupilumab and identify predictors of its effectiveness in real-world settings using two type-2 biomarkers: FeNO concentration and blood eosinophil count.
METHODS
METHODS
This prospective multicenter study included 103 patients with severe asthma. Exacerbations and respiratory functions were monitored for 24 weeks. Asthma control was evaluated using the Asthma Control Questionnaire-5. Clinical symptoms and their impact on cough and sputum were assessed using the Cough and Sputum Assessment Questionnaire (CASA-Q). Subgroup analyses of type-2 biomarkers were conducted based on FeNO levels and blood eosinophil counts at baseline.
RESULTS
RESULTS
Treatment with dupilumab led to a reduction in exacerbations and enhancement in asthma control, FEV
CONCLUSIONS
CONCLUSIONS
Type-2 biomarkers may act as indicators of improvement in FEV
Identifiants
pubmed: 39277433
pii: S1323-8930(24)00087-X
doi: 10.1016/j.alit.2024.08.005
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Japanese Society of Allergology. Published by Elsevier B.V. All rights reserved.